Search research articles
Contact Us
Filters
Showing results (191-200 of 218) with videos related to
Page
of 22
Sort By:
ESC Heart Failure
|
June 23, 2018
Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH)
Anne-Catherine Pouleur, Stefan Anker, Dulce Brito, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
April 6, 2021
Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial
João Pedro Ferreira, Timothy Collier, Andrew L Clark, et al.
European Heart Journal
|
September 11, 2019
How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
Burkert Pieske, Carsten Tschöpe, Rudolf A de Boer, et al.
JACC. Heart Failure
|
September 10, 2025
Inferior Vena Cava Ultrasound to Guide Decongestion in Acute Decompensated Heart Failure: A Randomized Controlled Trial
Alexander Jobs, Tanja K Rausch, Inke R König, et al.
European Heart Journal
|
August 9, 2014
New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes
Michele Senni, Walter J Paulus, Antonello Gavazzi, et al.
JAMA Cardiology
|
September 20, 2023
Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical Trial
Jean-Luc Balligand, Dulce Brito, Oana Brosteanu, et al.
European Journal of Heart Failure
|
March 6, 2020
How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
Burkert Pieske, Carsten Tschöpe, Rudolf A de Boer, et al.
Lancet (London, England)
|
August 30, 2018
Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial
Friedrich Koehler, Kerstin Koehler, Oliver Deckwart, et al.
Journal of the American College of Cardiology
|
April 19, 2023
Clinical and Prognostic Relevance of Cardiac Wasting in Patients With Advanced Cancer
Alessia Lena, Ursula Wilkenshoff, Sara Hadzibegovic, et al.
JACC. Heart Failure
|
February 7, 2021
Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF
João Pedro Ferreira, Job Verdonschot, Ping Wang, et al.
Page
of 22
Search research articles
Search
Showing results (191-200 of 218) with videos related to
Sort By:
Page
of 22
ESC Heart Failure
|
June 23, 2018
Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH)
Anne-Catherine Pouleur, Stefan Anker, Dulce Brito, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
April 6, 2021
Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial
João Pedro Ferreira, Timothy Collier, Andrew L Clark, et al.
European Heart Journal
|
September 11, 2019
How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
Burkert Pieske, Carsten Tschöpe, Rudolf A de Boer, et al.
JACC. Heart Failure
|
September 10, 2025
Inferior Vena Cava Ultrasound to Guide Decongestion in Acute Decompensated Heart Failure: A Randomized Controlled Trial
Alexander Jobs, Tanja K Rausch, Inke R König, et al.
European Heart Journal
|
August 9, 2014
New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes
Michele Senni, Walter J Paulus, Antonello Gavazzi, et al.
JAMA Cardiology
|
September 20, 2023
Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical Trial
Jean-Luc Balligand, Dulce Brito, Oana Brosteanu, et al.
European Journal of Heart Failure
|
March 6, 2020
How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
Burkert Pieske, Carsten Tschöpe, Rudolf A de Boer, et al.
Lancet (London, England)
|
August 30, 2018
Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial
Friedrich Koehler, Kerstin Koehler, Oliver Deckwart, et al.
Journal of the American College of Cardiology
|
April 19, 2023
Clinical and Prognostic Relevance of Cardiac Wasting in Patients With Advanced Cancer
Alessia Lena, Ursula Wilkenshoff, Sara Hadzibegovic, et al.
JACC. Heart Failure
|
February 7, 2021
Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF
João Pedro Ferreira, Job Verdonschot, Ping Wang, et al.
Page
of 22